Loading
Virus-based Gene Therapy Research · Journal article
Die Onkologie · August 17, 2026
A consensus or society position rather than new primary data.
This is a clinical overview of neuroblastoma epidemiology, molecular risk factors, and treatment stratification based on established standards and emerging trials. It characterizes the disease as biologically heterogeneous with risk-adapted therapy but documents persistently poor outcomes in high-risk disease (~50% 5-year overall survival) despite intensive multimodal treatment, and notes a ~50% relapse rate with ~80% of relapsed patients experiencing further progression.
Journal article. Children with neuroblastoma, stratified by risk (low, intermediate, high) based on clinical and molecular features including MYCN and ALK status, chromosome 1p36 aberrations, and tumor RNA expression profiles..
Approximately 120 new cases diagnosed annually in Germany, representing 5–6% of all childhood cancers ~50% of patients relapse following successful first-line treatment ~80% of relapsed patients experience further relapse or disease progression
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize the marked biological heterogeneity of neuroblastoma and apply risk-adapted treatment strategies (observation/surgery for low-risk; chemotherapy and surgery for intermediate-risk; intensive multimodal therapy including autologous stem cell transplantation and anti-GD2 immunotherapy for high-risk disease). The persistently poor outcomes in high-risk disease underscore the need for emerging approaches such as ALK inhibitors, CAR T cell therapy, and peptide vaccination currently under evaluation in clinical trials.
A clinical review summarizing the epidemiology, biology, risk stratification, and current standard management of neuroblastoma, with identification of emerging therapeutic approaches and diagnostic modalities.
Quoted from the source exactly as published.
Clinicians should recognize the marked biological heterogeneity of neuroblastoma and apply risk-adapted treatment strategies (observation/surgery for low-risk; chemotherapy and surgery for intermediate-risk; intensive multimodal therapy including autologous stem cell transplantation and anti-GD2 immunotherapy for high-risk disease). The persistently poor outcomes in high-risk disease underscore the need for emerging approaches such as ALK inhibitors, CAR T cell therapy, and peptide vaccination currently under evaluation in clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Neuroblastoma is the most common extracranial solid tumor of childhood. It originates from precursor cells of the peripheral nervous system in the adrenal medulla or the sympathetic chain. Approximately 120 new cases are diagnosed annually in Germany, representing 5–6% of all childhood cancers. The disease is characterized by marked biological heterogeneity, with outcomes ranging from spontaneous regression and localized tumors to metastatic, treatment-refractory high-risk disease. Common metastatic sites include the bone marrow, bone, lymph nodes, liver, lungs, and the central nervous system. Diagnosis and risk stratification are based on clinical and molecular features, including MYCN and ALK status, chromosome 1p36 aberrations, and tumor RNA expression profiles. Treatment is risk adapted: low-risk patients are managed with observation or surgery alone and receive chemotherapy only in the case of progressive disease or threatening symptoms. Intermediate-risk patients receive chemotherapy, surgery, and in some cases radiotherapy. High-risk patients undergo intensive multimodal treatment consisting of induction chemotherapy, surgery, high-dose chemotherapy with autologous stem cell transplantation, radiotherapy, and anti-GD2 immunotherapy. Despite successful first-line treatment, ~50% of patients relapse, and ~80% of these patients experience further relapse or disease progression. The 5‑year overall survival rate for high-risk neuroblastoma remains only ~50%. Current clinical trials are evaluating chemoimmunotherapy in frontline and relapsed settings. Other promising approaches include ALK inhibitors for ALK-positive tumors, stem cell transplantation combined with anti-GD2 immunotherapy, chimeric antigen receptor (CAR) T cell therapy, and peptide vaccination. Diagnostic research focuses on liquid biopsy and 18 F‑meta-fluorobenzylguanidine positron-emission tomography computed tomography ([ 18 F]mFBG PET/CT) imaging.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.